MD4317C1 - Использование 3-(2, 2, 2-триметилгидразиний) пропионата дигидрат для лечения пациентов с прогрессирующим циррозом печени, ассоциированного с сердечной недостаточностью - Google Patents
Использование 3-(2, 2, 2-триметилгидразиний) пропионата дигидрат для лечения пациентов с прогрессирующим циррозом печени, ассоциированного с сердечной недостаточностью Download PDFInfo
- Publication number
- MD4317C1 MD4317C1 MDA20130064A MD20130064A MD4317C1 MD 4317 C1 MD4317 C1 MD 4317C1 MD A20130064 A MDA20130064 A MD A20130064A MD 20130064 A MD20130064 A MD 20130064A MD 4317 C1 MD4317 C1 MD 4317C1
- Authority
- MD
- Moldova
- Prior art keywords
- liver cirrhosis
- trimethylhydrazinium
- heart failure
- advanced liver
- day
- Prior art date
Links
- 208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 10
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 5
- JFWLFLLRLZSBRA-UHFFFAOYSA-N 3-[(trimethylazaniumyl)amino]propanoate;dihydrate Chemical compound O.O.C[N+](C)(C)NCCC([O-])=O JFWLFLLRLZSBRA-UHFFFAOYSA-N 0.000 title claims abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 230000000750 progressive effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 3
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000002425 cardiocirculatory effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002168 angioprotective effect Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- PPQFUDZMTNGHBJ-UHFFFAOYSA-N propanoic acid;dihydrate Chemical compound O.O.CCC(O)=O PPQFUDZMTNGHBJ-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к медицине, в частности к гепатологии.Согласно изобретению, заявляется использование 3-(2, 2, 2-триметилгидразиний) пропионата дигидрат для лечения прогрессирующего цирроза печени, ассоциированного с сердечной недостаточностью, внутривенно, по 500 мг, 1…2 раза в день, в течение 7…10 дней, затем per os,по 500 мг, 1…2 раза в день, в течение 4…6 недель.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20130064A MD4317C1 (ru) | 2013-09-12 | 2013-09-12 | Использование 3-(2, 2, 2-триметилгидразиний) пропионата дигидрат для лечения пациентов с прогрессирующим циррозом печени, ассоциированного с сердечной недостаточностью |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20130064A MD4317C1 (ru) | 2013-09-12 | 2013-09-12 | Использование 3-(2, 2, 2-триметилгидразиний) пропионата дигидрат для лечения пациентов с прогрессирующим циррозом печени, ассоциированного с сердечной недостаточностью |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD4317B1 MD4317B1 (ru) | 2015-01-31 |
| MD4317C1 true MD4317C1 (ru) | 2015-08-31 |
Family
ID=52440946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20130064A MD4317C1 (ru) | 2013-09-12 | 2013-09-12 | Использование 3-(2, 2, 2-триметилгидразиний) пропионата дигидрат для лечения пациентов с прогрессирующим циррозом печени, ассоциированного с сердечной недостаточностью |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD4317C1 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD4458C1 (ru) * | 2014-06-19 | 2017-08-31 | Мария ДАНУ | Использование препарата Полибиолин при лечении пациентов с циррозом печени |
-
2013
- 2013-09-12 MD MDA20130064A patent/MD4317C1/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MD4317B1 (ru) | 2015-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Riou et al. | Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity | |
| CN106176703A (zh) | 丹酚酸a在制备预防和/或治疗肺动脉高压中的药物用途 | |
| MD4317C1 (ru) | Использование 3-(2, 2, 2-триметилгидразиний) пропионата дигидрат для лечения пациентов с прогрессирующим циррозом печени, ассоциированного с сердечной недостаточностью | |
| CN108815171B (zh) | 25-羟基胆固醇在制备治疗或预防心肌梗死的药物中的应用 | |
| MD4232C1 (ru) | Лекарственное средство на основе троксерутина и карбазокрома для лечения прогрессирующего цирроза печени сопутствующего с сердечной недостаточностью | |
| CN103340863A (zh) | 烟酰胺在制备治疗糖尿病伤口愈合药物中的应用 | |
| CN117257803A (zh) | 鲁拉西酮在制备治疗或预防缺血/再灌注损伤的药物和细胞保护药物中的应用 | |
| CN104958360A (zh) | 一种心脑血栓通 | |
| CN111973643A (zh) | 一种三七总皂苷在制备治疗急性心肌梗死和/或伴发高血糖的药物中的应用 | |
| Reddy et al. | Bilateral nipple necrosis after intravenous vasopressin therapy | |
| Yamanaka et al. | Automatic remote ischemic preconditioning procedure reduces reperfusion arrhythmias and contrast-induced nephropathy in patients with ST-elevation myocardial infarction | |
| JP5923044B2 (ja) | 活性成分としてｌ−カルニチンまたはプロピオニルｌ−カルニチンを含む慢性静脈不全の予防または治療のための併用組成物 | |
| Alexopoulos et al. | Standard (180mg) vs high (360mg) loading dose of ticagrelor in patients with STEMI undergoing primary PCI | |
| Fadil et al. | Effect of remote ischemic postconditioning on left ventricular ejection fraction in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention | |
| CN107510840B (zh) | 含乌司他丁的组合物在制备治疗放化疗引起的皮肤损伤药物中的用途 | |
| CN103356646B (zh) | Chukrasone A在制备治疗急性肾衰药物中的应用 | |
| RU2578451C1 (ru) | Способ повышения устойчивости головного мозга к ишемии во время реконструктивных операций на брахиоцефальных артериях | |
| Babu et al. | Kampo Medicine for Hypertension and Related Disorders | |
| CN103446119B (zh) | Fluevirosines A在制备治疗急性肾衰药物中的应用 | |
| Xiang-yun et al. | Clinical Report: Oral Propranolol Combined with Topical Timolol Maleate for the Treatment of Compound Infantile Hemangioma in Parotid Region | |
| CN103610678B (zh) | Trigolutesins A在治疗心肌缺血药物中的应用 | |
| Lǚ et al. | Cardiac disorder in hemodialysis: benefits of Chinese herbs | |
| CN104383187B (zh) | 一种外用治疗胺碘酮所致静脉炎的药剂及其制备方法 | |
| Trimble et al. | Control of pulmonary hemorrhage by intravenous use of pituitrin | |
| RU2604409C1 (ru) | Способ терапии злокачественных новообразований |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued | ||
| KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |